A cholesterol injection study for people on dialysis
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 80 years old and can sign informed consent
- You have end-stage kidney disease and have been on dialysis for at least 3 months (no ongoing dialysis complications)
- You must be able to receive shots under the skin (no reason you can’t have subcutaneous injections)
- Your LDL (“bad cholesterol”) must be at least 70 mg/dL to join
- No heart attack, stent (PCI), bypass (CABG), stroke/TIA, or blocked leg artery events in the last 3 months
- If you can become pregnant: you must use very reliable birth control during dosing and for 2 weeks after the last shot
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a weekly injection of alirocumab (Praluent) is safe and effective for people with high cholesterol. It aims to help lower LDL cholesterol that has not responded enough to current treatment.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
This trial tests a new medicine, SHR-1918, for people whose bad cholesterol (LDL-C) stays high even when they take statins and another type of cholesterol-lowering drug called a PCSK9 inhibitor. It aims to see if this additional treatment can lower their cholesterol more effectively.
This study tracks how well patients stick to and benefit from alirocumab 300mg, a cholesterol-lowering injection. It looks at real-world use in Italy.
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Hear when a new Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.